AvenCell Therapeutics, a clinical-stage cell therapy company developing switchable CAR-T therapies for cancer, today announced that data from the completed Phase 1a portion of the RevSTAR-123 study, ...
Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T therapy, as an off-the-shelf, ...
With Innovent Biologics garnering buzz in the dealmaking space, Ta | Takeda and Innovent's long-term follow-up data from an ...
Autogefühl on MSN
Is the Mercedes E-Class still worth buying?
The Mercedes E-Class remains one of the premium sedans worth considering thanks to its mix of comfort, elegant design, modern ...
Researchers demonstrated that blocking multiple RAS mutations with daraxonrasib can extend survival in patients with ...
A first-in-class bispecific antibody-drug conjugate that Bristol Myers Squibb paid $800 million for has shown strong phase 3 ...
Eli Lilly and Company (NYSE: LLY) today announced the details of presentations at the European Hematology Association (EHA) ...
Three young men, all dressed in black suit-and-tie, pose with arms around each other on the edge of a lake. width=640 srcset= ...
Arc G3 Extreme delivers outstanding performance at 1080p inside the MSI Claw 8 EX AI - and what sounds like impressive ...
And in any honest account of the recent chemical scare in Garden Grove, “if” is huge. If Orange County Fire Agency responders ...
Iza-bren is a potentially first-in-class bispecific ADC designed to target both EGFR and HER3. It features high affinity for ...
The Trump company announced Monday a new business, Trump Mobile, that will offer cell service in a licensing deal and sell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results